Kintara Therapeutics 2024 EPS $(0.32) Up From $(9.27) YoY; Cash And Cash Equivalents $4.9M
Portfolio Pulse from Benzinga Newsdesk
Kintara Therapeutics has improved its EPS from $(9.27) to $(0.32) year-over-year and holds $4.9M in cash. The company is set to merge with TuHURA Biosciences, with the merger expected to complete in mid-October 2024. Kintara is also progressing with its REM-001 study, supported by a $2M NIH grant.
October 08, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kintara Therapeutics is set to merge with TuHURA Biosciences, which could enhance its oncology portfolio. The merger is expected to close in mid-October 2024. Kintara's EPS has improved significantly, and it is advancing its REM-001 study with NIH funding.
The merger with TuHURA Biosciences is a significant development for Kintara, potentially expanding its oncology capabilities. The improved EPS indicates better financial health, and the NIH grant supports ongoing research, all of which are positive indicators for Kintara's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100